a substantially pure antibody binding an RSV F glycoprotein epitope, wherein said antibody comprises a heavy chain CDR3 region having the amino acid sequence of SEQ ID NO:7.

- 2. [AMENDED] The pharmaceutical composition of claim 1 wherein said antibody comprises an Fd fragment.
- 3. [AMENDED] The pharmaceutical composition of claim 1 wherein said antibody comprises an Fab fragment.
- 4. [AMENDED] The pharmaceutical composition of claim 1 wherein said antibody includes a heavy chain CDR2 region comprising the amino acid sequence of SEQ ID NO:5.
- 5. [AMENDED] The pharmaceutical composition of claim 1 wherein said antibody comprises a heavy chain CDR1 region having the amino acid sequence of SEQ ID NO:3.
- 6. [AMENDED] The pharmaceutical composition of claim 1 wherein said antibody comprises a heavy chain Fd region having the amino acid sequence of SEQ ID NO:1.
- 7. [AMENDED] The pharmaceutical composition of claim 1 wherein said antibody comprises a light chain CDR3 region having the amino acid sequence of SEQ ID NO:15.
- 8. [AMENDED] The pharmaceutical composition of claim 1 wherein said antibody comprises a light chain CDR2 region having the amino acid sequence of SEQ ID NO:13.